Q-omics provides the consensus-scored MYL6 profile across patient tissues and cancer cell-line models. MYL6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYL6 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MYL6 protein abundance shows 35,463 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, BLCA, and PDAC as cancer lineages where MYL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL6 survival associations across molecular data types. MYL6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL6 RNA expression–survival associations across cancer types. High MYL6 expression shows unfavorable associations in UVM, ACC, KICH, MESO, LGG and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MYL6 RNA expression.
This table summarizes MYL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL6 shows lower tumor expression in BLCA, KICH, COAD, LUSC and LUAD and higher tumor expression in LIHC. The BLCA box plot shows higher MYL6 RNA expression in normal versus tumor tissue (log2 FC = −1.524, t-test p < 0.001).
This table shows molecular features associated with MYL6 in patient tissues and cancer cell lines. In patient samples, MYL6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
